The positive association may be explained by reverse causation whereby prostate cancer is already disrupting glucose control shortly before diagnosis, causing the patient to initiate metformin use or increase his dose, or by surveillance bias, whereby, before initiating metformin treatment or increasing the dose, clinicians performed more extensive checks of their patients, including prostate-specific antigen examination. This evidence concerns the gene KLK3 and prostate cancer.